Hepatitis C Drugs Market Research Report Information, By Drug Class (Anti-Viral, Immuno-modulators and others), By Medicine System (Allopathic, Alternative and Others), By Route of Administration (Oral, Injectable and others) and By End User (Hospitals and Private) - Forecast Till 2032

Global Hepatitis C Drugs Market Overview

Hepatitis C Drugs Market Size was valued at USD 26.65 Billion in 2023. The Global Hepatitis C Drugs industry is projected to grow from USD 27.21 Billion in 2024 to USD 32.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.60% during the forecast period (2024 - 2032). Hepatitis is inflammation of the liver portrayed by yellowed eyes and skin because of bilirubin, influenza like side effects which incorporate sickness, heaving, unfortunate hunger, joint agony, migraines, hued dirt stools and so on.

Hepatitis is brought about by various variables, both microbial and non-microbial. But hepatitis C is brought about by hepatitis C infection and influences between 130-150 million individuals internationally each extended time, of which roughly 700 000 individuals pass on from hepatitis C-related liver illnesses. What is of more prominent concern is the way that 15 to 20% of persistently tainted patients foster liver cirrhosis or liver malignant growth.

The hepatitis C drugs market size is driven by variables such as illness pervasiveness, ascend in government sponsorship and repayment, particularly in the U.S., more prominent screening, particularly in non-industrial countries, illicit drug use, and hazardous sex so forth.

In any case, the restrictions are overpowering, for example, the self-impersonating nature of the sickness in a sizable number of patients, the challenge of domestic therapy presented at insignificant costs, particularly in creating areas, cost battle between organizations, for example, among Gilead and Merck, rising urbanization and better disinfection and so on.

In this way, the Hepatitis C Drugs Market in created locales seems to arrive at a level as the number of individuals impacted isn't ascending in created districts. The re-assessment of the hepatitis C technique by organizations, for example, Boehringer Ingelheim and its choice to shun pushing ahead in hepatitis C examination, also means dormancy in created locale markets.

The Hepatitis C Drugs Market share is likewise unitary with a couple of predominant players, for example, Gilead with a couple of brands, Sovaldi, Harvoni and so forth, driving the market. The improvement pipeline is solid in the immunization section. It is normal that an antibody will make its invasion sooner rather than later, as occurred with different types of hepatitis.

The World Health Organization gave out new guidelines in July 2021, advising that HCV self-testing should be added to the currently existing HCV testing services. The WHO’s first-ever guidelines on HCV self-testing were released during the IAS conference 2021. Despite this, it was the aim of WHO in its Global Health Sector strategy on viral hepatitis (2016–2021) to eliminate hepatitis C as a public health threat by 2030 by diagnosing ninety percent and treating eighty percent of infected individuals. By then, however, fewer than one quarter (21%) of an estimated 58 million people with chronic infection had been diagnosed. Furthermore, about thirty two per cent only received treatment between this time despite more effective and cheaper DAA medications available as compared to nine point four million (62%) cases treated with DAAs from 2015 to 2019.

Hepcinat Plus under brand name Sofosbuvir-Daclatasvir tablets combination for Hepatitis C treatment has been introduced into India by Natco Pharma in July 2018. This is a generic fixed-dose combination drug containing Sofosbuvir 400 mg and Daclatasvir 60mg tablets for the management of patients suffering from chronic hepatitis c virus infections (HCV), according to BSE filing. It further said that this drug would be sold at a maximum retail price (MRP) of ₹17,500 per bottle containing twenty-eight tablets.

In November 2023, release of WHO’s initial-ever listing on priority pediatric formulations for five neglected tropical diseases (NTDs) guides research and development towards addressing the special requirements faced by babies up to today year after year. These include human African trypanosomiasis, onchocerciasis, scabies, schistosomiasis, and visceral leishmaniasis. WHO’s “Paediatric Drug Optimization” exercise resulted in this list, which took place over three to five years(PADO priority list) or within five to ten years (PADO watch list). The first step necessary in prioritization is targeting research and development that goes hand in hand with developing or updating normative guidance on medicine used to treat and prevent communicable and non-communicable diseases.

Covid-19 Analysis:

The effect of COVID-19 on Hepatitis C Drugs Market analysis for the year 2020 with a viral disease brought about by hepatitis C infection (HCV). 

Hepatitis C infection is a blood-borne infection that causes liver illness and can cause intense and ongoing hepatitis. The disease might be caused by infusion drug use, bonding of unscreened blood items, hazardous infusion rehearses, sexual contact and from contaminated mother to her child.

Finding HCV contamination should be possible by evaluating for hostility to HCV antibodies alongside a serological test to affirm the viral disease. Nucleic analysis for HCV ribonucleic corrosive (RNA) is acted if there should arise an occurrence of positive test results for hostile to HCV antibodies to affirm constant contamination.

Since there is no immunization accessible for HCV contamination, the World Health Organization (WHO) prescribes blood tests to screen patients that are at an expanded gamble of HCV disease and lessen the gamble of HCV openness in medical care settings. Screening of pregnant individuals for HCV is the standard of care in many nations and is viewed as a practical technique for decreasing the gamble of transmission to the child.

Hepatitis C Drugs Market Trends

• Key Market Drivers

Agricultural nations, for example, India, China and Brazil, have an enormous patient pool contrasted with other created nations. This increments interest in hepatitis C treatment drugs. Not many nations and state legislatures have taken drives to control hepatitis C contamination by sponsoring drugs or by giving exceptional assets towards sickness therapy programs. Different private NGOs make mindfulness and teach the populace to help battle the hepatitis C disease. These may likewise be considered drivers for the Hepatitis C treatment market.

The pervasiveness of hepatitis C contamination among people worldwide is expanding. This is fundamentally brought about by sharing needles, unsterilized clinical gear, and blood bonding channels from contaminated mother to newly conceived child.

• Market Challenges:

In hepatitis C disease treatment, there are around 2300 atoms in pipeline studies and around 300 in stage 4 investigations. Different organizations are engaging in the advancement of hepatitis C treatment prescription. This would prompt the advancement of new items, which eventually drives the Hepatitis C Drugs Market.

• Market Opportunities

Various nations have different guideline bodies to endorse drugs for illness treatment. Because of this, drugs are not handily supported on the lookout, influencing the accessibility of items on the lookout; as per The United States Attorney General (A.G.), over half of the specialists who endorsed Harvoni were denied inclusion by their guarantor. Protection suppliers deny repayment demands because of the high treatment cost. In addition, payers repay a tiny measure of the all-out cost of the treatment, which eventually diminishes, generally speaking, business sector size.

• Market Restraints:

The significant expense of drugs is the top restriction for the Hepatitis C Drugs Market, as the cost of the treatment is a lot higher, and everyone can't manage the cost of the treatment. For instance, the cost of Harvoni (Ledipasvir and Sofosbuvir) medication is US$ 94,500 for a 12-week treatment, which is around US$ 1100 for each pill. Rigid administrative standards prevent early endorsements and crash commercialization of items, which eventually hampers market development.

Hepatitis C Drugs Market Segment Insights

On the basis of drug class which comprises anti-viral, immuno-modulators and others. 

Hepatitis C Drugs Medical System Insights

On the basis of the medical system, the market is segmented into allopathic, alternative and others. On the basis of route of administration, the market is segmented into oral, injectable and others. 

Hepatitis C Drugs End-User Insights

On the basis of end-user, the market is segmented into hospitals and private. By drug class, the hepatitis C drugs market trends fragment represented around 66.2% portion of the general market esteem in 2015. By circulation channel, the medical clinic drug stores fragment is assessed to represent the most elevated portion of the overall industry of 42.8% of the worldwide hepatitis C therapy market by the 2016 end, while the retail drug stores section is assessed to represent 34.2% piece of the pie in 2016.

Hepatitis C Drugs Regional Insights

Around the world, America is the biggest Hepatitis C Drugs Market forecast. Europe is the second-biggest market for Hepatitis C drugs. The created locales market is relied upon to stay stale and even may show negative CAGR because of falling patient numbers. In this manner, the emerging countries' market will show moderate development and is relied upon to get on the created areas. China and India will drive the Asia Pacific locale. Africa is relied upon to be a loafer in the hepatitis C market.

Key Companies in the Hepatitis C Drugs market include

• AbbVie Inc.


• Bristol-Myers Squibb Company


• F Hoffmann-La Roche Ltd


• Gilead Sciences, Inc.


• Johnson and Johnson,


• Kadmon Holdings, Inc.


• Merck and Co., Inc.

The Hepatitis C Drugs Market is combined with a couple of vital participants wherein Gilead Sciences, Inc. contributes around 80.1% of the piece of the pie, producing a greater part of the income from the deals of drugs Harvoni and Sovaldi, followed by Bristol-Myers Squibb Company and AbbVie Inc.

Hepatitis C Drugs Industry Developments

In January 2024,

Bristol-Myers Squibb announced that the FDA granted Breakthrough Therapy Designation to their investigational drug, BMS-986036, for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 3, and 4 who have previously failed treatment with other DAA regimens. This designation is based on preliminary clinical trial data showing promising efficacy and safety.

In December 2023,

Roche announced the submission of a New Drug Application (NDA) to the FDA for pangenotypic ledipasvir/ritonavir (LDV/r) for the treatment of chronic HCV infection in adults. LDP/r is a fixed-dose combination tablet that combines ledipasvir, an NS5A inhibitor, and ritonavir, a pharmacokinetic enhancer. This submission follows positive Phase 3 clinical trial results demonstrating high rates of SVR with LDP/r across all major HCV genotypes.

Report Overview:

The report for Hepatitis C Drugs Market outlook concentrates on showing the accompanying targets.

Hepatitis C Drugs Market

• To give a detailed examination of the market structure alongside conjecture for the following 7 years of the different fragments and sub-sections of the Hepatitis C drugs market.


• To give bits of knowledge about factors influencing the market development.


• To dissect the market in view of different variables cost examination, inventory network investigation, watchmen five power examination, etc.


• To give verifiable and figure income of the market fragments and sub-sections concerning four principal geologies and their nations Americas, Europe, Asia-Pacific, and the Middle East and Africa.


• To give a country-level examination of the market as for the current market size and future forthcoming.


• To give a country level investigation of the market for fragments by drug class (hostile to viral, immuno-modulators and others), by medication framework (allopathic, option and others), by course of the organization (oral, injectable and others) and by the end client (clinics and private)


• To give an outline of vital participants and their essential profiling on the lookout, extensively examining their center capabilities, and drawing a cutthroat scene for the market.


• To follow and break down cutthroat advancements like joint endeavors, vital partnerships, consolidations and acquisitions, new item improvements, and exploration and advancements around the world.